Potential genotype-specific single nucleotide polymorphism interaction of common variation in p53 and its negative regulator mdm2 in cholangiocarcinoma susceptibility

Oncology Letters

Volumn 4, Issue 1, 2012, Pages 101-106

  Zimmer, Vincent ^a   Höblinger, Aksana ^b   Mihalache, Florentina ^c   Assmann, Gunter ^a   Acalovschi, Monica ^c   Lammert, Frank ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Apoptosis; Biliary tract cancer; Cancer susceptibility; Cell cycle; Cholangiocarcinoma; Epistasis; Gene gene interaction; Genetic risk

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ALLELE; ARTICLE; BILE DUCT CARCINOMA; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENDER; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; REGULATOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR LOCALIZATION;

EID: 84861304205     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.680     Document Type: Article

References (34)

1. Khan SA, Thomas HC, Davidson BR and Taylor-Robinson SD: Cholangiocarcinoma. Lancet 366: 1303-1314, 2005.
2. Shaib Y and El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis 24: 115-125, 2004.
3. Cardinale V, Semeraro R, Torrice A, et al: Intra-hepatic and extra-hepatic cholangiocarcinoma: new insight into epidemiology and risk factors. World J Gastrointest Oncol 2: 407-416, 2010.
4. Valle J, Wasan H, Palmer DH, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362: 1273-1281, 2010.
5. Hezel AF, Deshpande V and Zhu AX: Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 28: 3531-3540, 2010.
6. Ortner MA: Photodynamic therapy for cholangiocarcinoma: overview and new developments. Curr Opin Gastroenterol 25: 472-476, 2009.
7. Gatto M, Bragazzi MC, Semeraro R, et al: Cholangiocarcinoma: update and future perspectives. Dig Liver Dis 42: 253-260, 2010.
8. Blechacz BR and Gores GJ: Cholangiocarcinoma. Clin Liver Dis 12: 131-150, 2008.
9. Mihalache F, Hoblinger A, Grunhage F, et al: Heterozygosity for the alpha1-antitrypsin Z allele may confer genetic risk of cholangiocarcinoma. Aliment Pharmacol Ther 33: 389-394, 2011.
10. Zhou H, Ortiz-Pallardo ME, Ko Y and Fischer HP: Is heterozygous alpha-1-antitrypsin deficiency type PIZ a risk factor for primary liver carcinoma? Cancer 88: 2668-2676, 2000.
11. Hoblinger A and Lammert F: Genetics of biliary tract diseases: new insights into gallstone disease and biliary tract cancers. Curr Opin Gastroenterol 24: 363-371, 2008.
12. Blechacz B and Gores GJ: Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 48: 308-321, 2008.
13. Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell 140: 883-899, 2010.
14. Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature 408: 307-310, 2000.
15. Komarova EA, Krivokrysenko V, Wang K, et al: p53 is a suppressor of inflammatory response in mice. FASEB J 19: 1030-1032, 2005.
16. Gudkov AV and Komarova EA: Dangerous habits of a security guard: the two faces of p53 as a drug target. Hum Mol Genet 16 Spec No 1: R67-R72, 2007.
17. Khan SA, Taylor-Robinson SD, Carmichael PL, Habib N, Lemoine NR and Thomas HC: Analysis of p53 mutations for a mutational signature in human intrahepatic cholangiocarcinoma. Int J Oncol 28: 1269-1277, 2006.
18. Khan SA, Thomas HC, Toledano MB, Cox IJ and Taylor-Robinson SD: p53 Mutations in human cholangiocarcinoma: a review. Liver Int 25: 704-716, 2005.
19. Tannapfel A, Weinans L, Geissler F, et al: Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver. Dig Dis Sci 45: 317-324, 2000.
20. Farazi PA, Zeisberg M, Glickman J, Zhang Y, Kalluri R and DePinho RA: Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res 66: 6622-6627, 2006.
21. Whibley C, Pharoah PD and Hollstein M: p53 polymorphisms: cancer implications. Nat Rev Cancer 9: 95-107, 2009.
22. Bond GL, Hu W, Bond EE, et al: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602, 2004.
23. Dumont P, Leu JI, Della Pietra AC III, George DL and Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365, 2003.
24. Khan SA, Davidson BR, Goldin R, et al: Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51 (Suppl 6): 1-9, 2002.
25. Hartman M, Loy EY, Ku CS and Chia KS: Molecular epidemiology and its current clinical use in cancer management. Lancet Oncol 11: 383-390, 2010.
26. Hattersley AT and McCarthy MI: What makes a good genetic association study? Lancet 366: 1315-1323, 2005.
27. Bond GL, Hirshfield KM, Kirchhoff T, et al: MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66: 5104-5110, 2006.
28. Bond GL and Levine AJ: A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 26: 1317-1323, 2007.
29. Zimmer V, Widmann T, Muller M, et al: Genotypic interaction and gender specificity of common genetic variants in the p53/mdm2 network in Crohn's disease. Digestion 81: 246-251, 2010.
30. Jones JS, Chi X, Gu X, Lynch PM, Amos CI and Frazier ML: p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res 10: 5845-5849, 2004.
31. Shen H, Zheng Y, Sturgis EM, Spitz MR and Wei Q: P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett 183: 123-130, 2002.
32. Welzel TM, Graubard BI, El-Serag HB, et al: Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 5: 1221-1228, 2007.
33. Thomas M, Kalita A, Labrecque S, Pim D, Banks L and Matlashewski G: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19: 1092-1100, 1999.
34. Pim D and Banks L: p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108: 196-199, 2004.